NMTR - 9 meters Biopharma announces deal for Phase 3 trial of celiac disease treatment

9 Meters Biopharma (NASDAQ:NMTR) said on Wednesday it had tied-up with Celiac.com, a website for gluten-free diet due to celiac disease, to help support clinical trial enrollment for its drug candidate larazotide to treat the gluten sensitivity disease. The drug is currently in late-stage trial to evaluate the safety and efficacy in adult patients with at least a six-month history of celiac disease who continue to experience gastrointestinal symptoms despite maintaining a gluten-free diet. "An interim analysis to confirm study sample size assumptions is anticipated to be completed in early June," the company said.  Celiac disease is an autoimmune gastrointestinal disease characterized by an inflammatory response to dietary gluten, causing abdominal pain and gas. Last week, the company's stock rose 19% on US patent for NM-136 to treat metabolic disorders. (NMTR +1.5%)

For further details see:

9 meters Biopharma announces deal for Phase 3 trial of celiac disease treatment